10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study groupMichael Lübbert, Gerwin Huls, Mario Luppi et al.|Blood|2025Cited by 1